Chunlin Chen

发表

The pharmacokinetics of oral trazpiroben (TAK‐906) after organic anion transporting polypeptide 1B1/1B3 inhibition: A phase I, randomized study

C. Almansa, D. Ramsden, Susanna Y. Huh, 2022, Clinical and translational science.

Evaluation of the pharmacokinetics of trazpiroben (TAK‐906) in the presence and absence of the proton pump inhibitor esomeprazole

Polyna Khudyakov, M. Nishihara, G. Dukes, 2022, Clinical and translational science.

Randomised study: effects of the 5‐HT4 receptor agonist felcisetrag vs placebo on gut transit in patients with gastroparesis

M. Camilleri, W. Harmsen, D. Burton, 2021, Alimentary pharmacology & therapeutics.

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial

S. Vermeire, G. D'Haens, F. Baert, 2021, Journal of Crohn's & colitis.

Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor

C. Almansa, M. Bari, M. Rosario, 2021, Clinical pharmacology : advances and applications.

A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease

P. Chevallier, I. Yakoub-Agha, M. Mohty, 2021, Bone Marrow Transplantation.

Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Yi-Bin Chen, S. Devine, C. Cutler, 2019, Blood advances.

Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn’s Disease: Results from the Phase 2 HUBBLE Study

D. Turner, J. Hyams, S. Kabilan, 2022, Journal of Crohn's & colitis.

Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK‐906), a dopamine D2/D3 receptor antagonist, in patients with gastroparesis

M. Camilleri, B. Kuo, G. Dukes, 2021, Alimentary pharmacology & therapeutics.

Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK‐906), a Novel Selective D2/D3 Receptor Antagonist: A Phase 1 Randomized, Placebo‐Controlled Single‐ and Multiple‐Dose Escalation Study in Healthy Participants

B. Darpo, D. Combs, R. Whiting, 2021, Clinical pharmacology in drug development.

Evaluation of the Pharmacokinetics of Felcisetrag (TAK‐954), a 5‐HT4 Receptor Agonist, in the Presence and Absence of Itraconazole, a Potent CYP3A4 Inhibitor

C. Almansa, M. Cwik, S. Balani, 2022, Clinical pharmacology in drug development.